Mitochondrial beta-oxidation enzymes (mFAO enzymes)

Mitochondrial beta-oxidation enzymes comprise a multi-step catalytic pathway responsible for the breakdown of long-chain fatty acids into acetyl-CoA, NADH, and FADH2. This process is essential for energy production, particularly in the heart and skeletal muscle during periods of fasting or prolonged exercise (StatPearls, 2023). The pathway involves four recurring reactions: oxidation, hydration, a second oxidation, and thiolysis, catalyzed by enzymes such as acyl-CoA dehydrogenases and the mitochondrial trifunctional protein (PubMed, PMID: 24303109). Genetic deficiencies in these enzymes result in metabolic crises, while pharmacological modulation is a key strategy in cardiovascular medicine. Drugs like trimetazidine and ranolazine partially inhibit these enzymes to promote glucose oxidation, which is more oxygen-efficient than fatty acid oxidation, providing a cytoprotective effect in patients with chronic stable angina (NCBI, NBK559267). Additionally, these enzymes are being investigated as targets in oncology, as certain tumors rely on fatty acid oxidation for survival and metastasis (PubMed, PMID: 31506330). Therapeutic challenges include the risk of systemic metabolic disruption, such as hypoglycemia or lipid accumulation in the liver, when these enzymes are inhibited (NIH, 2022).

Other names

Fatty acid beta-oxidation enzymesMitochondrial fatty acid oxidation pathwayBeta-oxidation cycle enzymespFOX (Partial Fatty Acid Oxidation) targets

Partial inhibition of the beta-oxidation cycle (specifically 3-ketoacyl-CoA thiolase) to shift cellular metabolism from fatty acid oxidation to glucose oxidation; inhibition of carnitine-dependent transport of fatty acids into the mitochondria.